Literature DB >> 27260615

Performance-Based Agreements in Italy: 'Trendy Outcomes' or Mere Illusions?

Livio Garattini1, Alessandro Curto2.   

Abstract

Mesh：

Year:  2016        PMID： 27260615     DOI： 10.1007/s40273-016-0420-1

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN： 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  10 in total

1.  The pharmaceutical industry--prices and progress.

Authors:  F M Scherer
Journal:  N Engl J Med       Date:  2004-08-26       Impact factor: 91.245

2.  Multiple sclerosis risk sharing scheme: a costly failure.

Authors:  James Raftery
Journal:  BMJ       Date:  2010-06-03

3.  MONITORING REGISTRIES AT ITALIAN MEDICINES AGENCY: FOSTERING ACCESS, GUARANTEEING SUSTAINABILITY.

Authors:  Simona Montilla; Entela Xoxi; Pierluigi Russo; Americo Cicchetti; Luca Pani
Journal:  Int J Technol Assess Health Care       Date:  2015-01       Impact factor: 2.188

4.  Can't get no satisfaction? Will pay for performance help?: toward an economic framework for understanding performance-based risk-sharing agreements for innovative medical products.

Authors:  Adrian Towse; Louis P Garrison
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

5.  Market-access agreements for anti-cancer drugs.

Authors:  Katelijne van de Vooren; Alessandro Curto; Nick Freemantle; Livio Garattini
Journal:  J R Soc Med       Date:  2014-12-08       Impact factor: 5.344

Review 6.  Do the current performance-based schemes in Italy really work? "Success fee": a novel measure for cost-containment of drug expenditure.

Authors:  Andrea Navarria; Valentina Drago; Lucia Gozzo; Laura Longo; Silvana Mansueto; Giacomo Pignataro; Filippo Drago
Journal:  Value Health       Date:  2014-11-11       Impact factor: 5.725

7.  Italian risk-sharing agreements on drugs: are they worthwhile?

Authors:  Livio Garattini; Alessandro Curto; Katelijne van de Vooren
Journal:  Eur J Health Econ       Date:  2015-01

8.  'Appropriateness' in Italy: A 'Magic Word' in Pharmaceuticals?

Authors:  Livio Garattini; Anna Padula
Journal:  Appl Health Econ Health Policy       Date:  2017-02       Impact factor: 2.561

9.  Authors' Reply to Palozzo and Messori: ''Disinvestment and Value-Based Purchasing Strategies for Pharmaceuticals: An International Review''.

Authors:  Bonny Parkinson; Adam G Elshaug
Journal:  Pharmacoeconomics       Date:  2016-04       Impact factor: 4.981

Review 10.  Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers.

Authors:  Jakub Adamski; Brian Godman; Gabriella Ofierska-Sujkowska; Bogusława Osińska; Harald Herholz; Kamila Wendykowska; Ott Laius; Saira Jan; Catherine Sermet; Corrine Zara; Marija Kalaba; Roland Gustafsson; Kristina Garuolienè; Alan Haycox; Silvio Garattini; Lars L Gustafsson
Journal:  BMC Health Serv Res       Date:  2010-06-07       Impact factor: 2.655
  10 in total
  9 in total

1.  Pharmaceutical pricing conundrum: time to get rid of it?

Authors:  Livio Garattini; Anna Padula
Journal:  Eur J Health Econ       Date:  2018-11

2.  Multi-Indication Pricing: Nice in Theory but Can it Work in Practice?

Authors:  Jorge Mestre-Ferrandiz; Néboa Zozaya; Bleric Alcalá; Álvaro Hidalgo-Vega
Journal:  Pharmacoeconomics       Date:  2018-12       Impact factor: 4.981

3.  Comparison of United States and International Ophthalmic Drug Pricing.

Authors:  Dan Gong; Jonathan S Chang; Miriam Barbany; Borja F Corcostegui; Mehmet Fatih Kağan Değirmenci; Hiroto Ishikawa; Zaid Mammo; Emin Ozmert; Tommaso Rossi; Stanley Chang
Journal:  Ophthalmology       Date:  2019-05-27       Impact factor: 12.079

Review 4.  Adaptive Pathways: Possible Next Steps for Payers in Preparation for Their Potential Implementation.

Authors:  Patricia Vella Bonanno; Michael Ermisch; Brian Godman; Antony P Martin; Jesper Van Den Bergh; Liudmila Bezmelnitsyna; Anna Bucsics; Francis Arickx; Alexander Bybau; Tomasz Bochenek; Marc van de Casteele; Eduardo Diogene; Irene Eriksson; Jurij Fürst; Mohamed Gad; Ieva Greičiūtė-Kuprijanov; Martin van der Graaff; Jolanta Gulbinovic; Jan Jones; Roberta Joppi; Marija Kalaba; Ott Laius; Irene Langner; Ileana Mardare; Vanda Markovic-Pekovic; Einar Magnusson; Oyvind Melien; Dmitry O Meshkov; Guenka I Petrova; Gisbert Selke; Catherine Sermet; Steven Simoens; Ad Schuurman; Ricardo Ramos; Jorge Rodrigues; Corinne Zara; Eva Zebedin-Brandl; Alan Haycox
Journal:  Front Pharmacol       Date:  2017-08-23       Impact factor: 5.810

5.  The Implementation of Managed Entry Agreements in Central and Eastern Europe: Findings and Implications.

Authors:  Alessandra Ferrario; Diāna Arāja; Tomasz Bochenek; Tarik Čatić; Dávid Dankó; Maria Dimitrova; Jurij Fürst; Ieva Greičiūtė-Kuprijanov; Iris Hoxha; Arianit Jakupi; Erki Laidmäe; Olga Löblová; Ileana Mardare; Vanda Markovic-Pekovic; Dmitry Meshkov; Tanja Novakovic; Guenka Petrova; Maciej Pomorski; Dominik Tomek; Luka Voncina; Alan Haycox; Panos Kanavos; Patricia Vella Bonanno; Brian Godman
Journal:  Pharmacoeconomics       Date:  2017-12       Impact factor: 4.981

6.  Evolution of Average European Medicine Prices: Implications for the Methodology of External Price Referencing.

Authors:  Sabine Vogler; Peter Schneider; Nina Zimmermann
Journal:  Pharmacoecon Open       Date:  2019-09

7.  Impact of Managed Entry Agreements on availability of and timely access to medicines: an ex-post evaluation of agreements implemented for oncology therapies in four countries.

Authors:  Olina Efthymiadou; Panos Kanavos
Journal:  BMC Health Serv Res       Date:  2022-08-20       Impact factor: 2.908

8.  Mapping of Current Obstacles for Rationalizing Use of Medicines (CORUM) in Europe: Current Situation and Potential Solutions.

Authors:  Mohamed Gad; Ahmed Salem; Wija Oortwijn; Ruaraidh Hill; Brian Godman
Journal:  Front Pharmacol       Date:  2020-03-03       Impact factor: 5.810

9.  How Risky Is That Risk Sharing Agreement? Mean-Variance Tradeoffs and Unintended Consequences of Six Common Risk Sharing Agreements.

Authors:  Gregory S Zaric
Journal:  MDM Policy Pract       Date:  2021-02-09
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.